Abstract 81: Initial Single-Pill vs Free-Pill Combination Therapy and Cardiovascular and Kidney Outcomes in Young Adults With Hypertension
Hypertension · 2026-10 · 83 (Suppl_1)
DOI: 10.1161/hyp.83.suppl_1.81 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Kyoung Hwa Ha und 4 weiteren Autor:innen.
Abstract (Originalsprache)
OBJECTIVES: Single-pill combination (SPC) antihypertensive therapy is recommended as first-line in many guidelines to reduce clinical inertia and nonadherence, which are key barriers to hypertension control in young adults. We evaluated the comparative effectiveness of initial SPC vs free-pill combination therapy for long-term cardiovascular disease (CVD) and kidney outcomes among young adults with hypertension. MATERIALS AND METHODS: Using the Korean National Health Insurance Service database, we conducted a retrospective cohort study with a new-user, active-comparator design among adults aged 20-49 years with hypertension and no prior CVD or chronic kidney disease (CKD). Participants who initiated antihypertensive therapy with angiotensin receptor blocker (ARB)/calcium channel blocker (CCB) combination therapy between 2009-2018 as either an SPC or two free pills were included and followed through 2024. Baseline covariates were balanced using inverse probability of treatment weighting. The primary outcomes were CVD events (hospitalization for myocardial infarction, stroke, heart failure, or cardiovascular death), kidney events (incident CKD, kidney replacement therapy, or kidney-related death), and the composite of CVD and kidney events. RESULTS: Among 127,495 participants initiating ARB/CCB, 116,133 initiated SPC and 11,362 initiated two free pills (mean age, 42.2 ± 5.4 years; 74.2% male). Over a median follow-up of 9.3 years (IQR, 7.8-11.9), 4,975 CVD events and 3,614 kidney events occurred. SPC initiation was associated with a 22% lower risk of incident CVD events (hazard ratio [HR], 0.78; 95% CI, 0.70-0.85), a 20% lower risk of kidney events (HR, 0.80; 95% CI, 0.71-0.90), and a 21% lower risk of the composite of CVD and kidney events (HR, 0.79; 95% CI, 0.73-0.85), compared with initiation as free pills. CONCLUSION: Among young adults with hypertension, initiation of SPC vs free-pill combination antihypertensive therapy was associated with lower risks of premature cardiovascular and kidney events.
Zitieren
APA
Ha, K. H., Cheon, D. Y., Son, D., Kim, H. C., & Lee, H. (2026). Abstract 81: Initial Single-Pill vs Free-Pill Combination Therapy and Cardiovascular and Kidney Outcomes in Young Adults With Hypertension. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.81
Vancouver
Ha KH, Cheon DY, Son D, Kim HC, Lee H. Abstract 81: Initial Single-Pill vs Free-Pill Combination Therapy and Cardiovascular and Kidney Outcomes in Young Adults With Hypertension. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.81
BibTeX
@article{Ha2026,
author = {Ha, Kyoung Hwa and Cheon, Dae Young and Son, Dasom and Kim, Hyeon Chang and Lee, Hokyou},
title = {Abstract 81: Initial Single-Pill vs Free-Pill Combination Therapy and Cardiovascular and Kidney Outcomes in Young Adults With Hypertension},
journal = {Hypertension},
year = {2026},
volume = {83},
number = {Suppl_1},
doi = {10.1161/hyp.83.suppl_1.81}
}
EUVIMED